(Source: ASHP - American Society of Health-System Pharmacists) BETHESDA, MD 22 Dec 2014- FDA and AbbVie on December 19 announced the approval of Viekira Pak, a four-drug oral combination product for the treatment of chronic hepatitis C infection in adults. Viekira Pak contains three new drugs-ombitasvir, paritaprevir, and dasabuvir-and the antiretroviral drug ritonavir, according to the product's labeling (PDF). Ombitasvir, a hepatitis C virus NS5A inhibitor, is formulated in a fixed-dose combination tablet along with the hepatitis C virus NS3/4A protease inhibitor paritaprevir...
↧